探讨乌司他丁治疗感染性休克临床疗效

The Investigation of Ulinastatin in Treatment of Septic Shock

目的探讨乌司他丁在感染性休克中的治疗作用。方法随机选择2014年2月—2016年6月该院收治的60例感染性休克患者为研究对象,随机分为治疗组和对照组各30例,两组患者均给予抗炎、扩容、血管活性药物及营养支持等常规治疗,治疗组在常规基础上给予乌司他丁静脉注射(每次10万单位,3次/d,连用7 d),比较两组患者治疗前及治疗7 d后血清降钙素原、C-反应蛋白、血乳酸水平变化情况,并对两组患者治疗14 d时死亡率进行比较。结果治疗7 d后,两组患者平均血清降钙素原、C-反应蛋白、血乳酸水平均较治疗前下降,但治疗组下降更为明显,两组比较差异均有统计学意义(P<0.05);治疗14 d时,治疗组死亡4例,死亡率为22%,对照组死亡14例,死亡率46.7%,治疗组死亡率明显低于对照组,差异有统计学意义(P<0.05)。结论在常规感染性休克治疗基础上联合乌司他丁能有效减轻炎症反应,改善临床症状。

Objective To explore the efficacy of ulinastastin on patients with Septic Shock. Methods Random selection clinical data of 60 patients with Septic Shock who were treated in Department of ICU from June 2014 to February 2016 were selected. All the cases were randomly divided into treatment group（n=30） and the control group（n=30）. All the patients in two groups were given basic medical treatment such as Anti-inflammatory treatment, Additional blood volume, Nutrition therapy and ect. The treatment group were given UTI treatment（100 000 U every time, three times a day, for 7 days）on the basis of routine treatment above. The change of C-reactive protein, Procalcitonin and Lactate level in two groups were observed respectively in two groups before and after the treatment and the mortality rate were also compared after the treatments. Results The level of C-reactive protein, Procalcitonin and Lactate in two groups were declined than before after7 days treatments, and the declining rate of patients in treatment group was much lower than that of control group（P〈0.05）.Meanwhile, the mortality rate of patients in treatment group（22%） was much lower than that in control group（46.7%）, and the difference was significant（P〈0.05）. Conclusion UTI on peptic shock can relieve inflammatory reaction and reduce mortality rate effectively on the basis of routine treatment